Latest Safety News

Carbonxt Group Limited has initiated a $2 million Share Purchase Plan following successful capital raises, aiming to bolster its Kentucky activated carbon facility as it nears commercial production.

New Hope Group delivered a robust quarterly performance with a 21.8% rise in underlying EBITDA and a 33% jump in saleable coal production for the first half of FY25, underpinned by operational efficiencies and strategic investments.

Neurizon Therapeutics received FDA guidance on its IND application for NUZ-001, with a single request for additional animal exposure data but no safety concerns flagged. The company is actively addressing the FDA’s request while evaluating impacts on its ALS trial timeline.

Aurizon’s half-year FY2025 results reveal a 4% EBITDA decline despite a 6% increase in coal volumes, alongside mixed safety outcomes and an extended $300 million buy-back program.

Aurizon Holdings posted a 3% revenue increase to $2.02 billion for 1HFY2025 but saw EBITDA dip 4% to $814 million, reflecting operational headwinds across key segments. The company declared a 9.2 cents per share interim dividend, signaling cautious optimism despite margin pressures.

BlueScope Steel reported a resilient $309 million underlying EBIT for 1H FY2025 despite depressed steel spreads, announcing a 30 cents per share interim dividend and extending its buy-back program. The company is targeting a $500 million incremental EBIT uplift by 2030 through cost initiatives and strategic growth projects.

BlueScope reported a $179 million net profit for 1H FY2025 amid challenging steel market conditions, while announcing a 30 cents per share dividend and a $240 million buy-back plan. The company is banking on cost initiatives and market recovery to boost earnings in the second half.

Westpac’s 1Q25 update reveals a resilient $1.7 billion net profit and strong loan growth despite margin pressures and economic headwinds.

LGI Limited reports a solid H1 FY25 performance with modest revenue growth and increased EBITDA, driven by expanded biogas flows and carbon abatement activities. The company confirms a positive outlook with a 12-15% underlying EBITDA growth forecast for FY25.

Imugene’s Phase 1b trial of azer-cel, an off-the-shelf CD19 CAR T therapy, reports a 57% complete response rate in heavily pretreated diffuse large B-cell lymphoma patients, signaling a promising new option in a challenging cancer landscape.

Austal Limited has landed a landmark A$270 million contract to design and build a 130-metre hydrogen-ready high-speed ferry for Sweden’s Gotlandsbolaget, marking a major step in sustainable maritime transport.

Cavalier Resources has completed and submitted all necessary mining approvals for the Crawford Gold Project, moving decisively toward production amid strong gold prices and ongoing funding talks.